Yearbook of pediatric endocrinology · 2020 · 40 citations · 18 references
Life SciencesMolecular MedicineNeurologyMedical GeneticsNeurodegenerationNeurogeneticsGenetic DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurogenetic DisordersNucleic Acid Drug DesignOligonucleotide DeliveryAntisense Oligonucleotide DesignEx Vivo DeliveryEx Vivo ModelsGene-targeted TherapyNeurological FunctionOligonucleotide TherapeuticsSeizuresSystemic Administration
This remarkable case report - by authors from Boston Childrens Hospital and funded by Milas Miracle Foundation - describes the development and use of a patient-customised antisense oligonucleotide drug that was tailored specifically against the unique DNA sequence mutation in a 6-year old girl with Batten disease, a degenerative neurological disease due to neuronal accumulation of lipofuscin and characterised by intractable seizures. They first tested the drug ex vivo, using cell lines from the patient, then showed that systemic administration reduced the frequency of seizures and halted her previously deteriorating neurological function.
18
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Richard S. Finkel, Eugenio Mercuri, Basil T. Darras et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Eugenio Mercuri, Basil T. Darras, Claudia A. Chiriboga et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text
Medicine, Neurology, Neuroscience +17
Landscape of Somatic Retrotransposition in Human Cancers
Eunjung Lee, Rebecca C. Iskow, Lixing Yang et al. · Science · 2012 · 778 citations
Timothy M. Miller, Alan Pestronk, William David et al. · The Lancet Neurology · 2013 · 607 citations · Full text
Medicine, Neurology, Pharmacology +17